about
Nanoparticulate adjuvants and delivery systems for allergen immunotherapyProtein corona - from molecular adsorption to physiological complexityEnhanced nasal mucosal delivery and immunogenicity of anti-caries DNA vaccine through incorporation of anionic liposomes in chitosan/DNA complexesA single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challengePolymeric Materials for Gene Delivery and DNA VaccinationIntranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae.Brucellosis: the case for live, attenuated vaccines.Activation of the ubiquitin proteasome pathway by silk fibroin modified chitosan nanoparticles in hepatic cancer cells.Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in miceInCVAX--a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunityChitosan but not chitin activates the inflammasome by a mechanism dependent upon phagocytosis.Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodiesChitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination.Nanoparticles as carriers for nasal vaccine delivery.Starch microparticles as vaccine adjuvant.The effect of antigen encapsulation in chitosan particles on uptake, activation and presentation by antigen presenting cellsIron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine.Chitin, chitosan, and glycated chitosan regulate immune responses: the novel adjuvants for cancer vaccineDesign opportunities for actively targeted nanoparticle vaccines.Applying the Taguchi design for optimized formulation of sustained release gliclazide chitosan beads: an in vitro/in vivo studyFolic acid-chitosan conjugated nanoparticles for improving tumor-targeted drug delivery.Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis.Studies on effect of pH on cross-linking of chitosan with sodium tripolyphosphate: a technical note.Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles.Chitosan as an Immunomodulating Adjuvant on T-Cells and Antigen-Presenting Cells in Herpes Simplex Virus Type 1 Infection.Chitosan and its salts for mucosal and transmucosal delivery.The application of mucoadhesive polymers in nasal drug delivery.The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants.A proteomic view to characterize the effect of chitosan nanoparticle to hepatic cells: is chitosan nanoparticle an enhancer of PI3K/AKT1/mTOR pathway?Progress towards a needle-free hepatitis B vaccine.Recent trends in oral transmucosal drug delivery systems: an emphasis on the soft palatal route.Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective.Recent progress towards development of a Shigella vaccine.The oral delivery of peptides and proteins: established versus recently patented approaches.Lymphatic system: a prospective area for advanced targeting of particulate drug carriers.Current understanding of synergistic interplay of chitosan nanoparticles and anticancer drugs: merits and challenges.Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.Mucosal vaccine delivery: Current state and a pediatric perspectiveDrug Release and Targeting: the Versatility of Polymethacrylate Nanoparticles for Peroral Administration Revealed by Using an Optimized In Vitro-Toolbox.Dry-powder form of chitosan nanospheres containing influenza virus and adjuvants for nasal immunization.
P2860
Q26825418-23E686D7-4E9A-474C-9233-F0914FF23F2CQ26853351-BAB467DC-AC73-482F-9870-2604D3F4157CQ27309096-1842DC7A-98BE-4A28-898F-3ACDDC40AE28Q33360151-A6BCFA2D-8642-428A-B38F-5280D3DECF50Q33565296-5F942A19-41F9-40BA-BF7B-6DC78CE51024Q34484116-FDEFFCAF-DAB6-4475-8BBE-CD8B4E479C0CQ34612868-79A3E45E-1B99-4B77-AE48-08203C0877E5Q35016649-59AB69B6-005F-4C54-94F7-7C4C8D5F4903Q35091726-2EDEB28B-41DC-4BE4-A77A-B581107C0C4FQ35108944-5F285787-0242-4A23-BEE9-B20AF43DFCC1Q35372472-61EFFBBA-5CB7-4C56-AB9F-8B7DCF5BE312Q35456892-ABD59924-0A1F-4DFC-9B21-15F7085637B3Q35839060-B14DF82A-97E9-490B-82AD-43A33AE099F6Q36124952-5657BE8A-2DD1-4247-8DA2-1A69D5F5AA90Q36316814-37F9D8A0-075D-4840-B063-C8D367D1901EQ36553255-817F7CC6-C83F-4E83-841E-5AA1EE11E611Q36615170-E8782DCC-D5A0-422D-805C-83890E230661Q36702887-8841F185-5B90-4593-A1DE-B3849DFA7664Q37062606-04F56D55-D7F9-4B84-9472-994F242D85FEQ37146176-95D48BE4-4F25-41A0-8011-642005AE8A63Q37300767-9A3CFE93-B6C6-4F0B-8947-AC554B3E7380Q37335446-2CBD2E1C-8846-4521-AC77-FEA2CBFF8D4FQ37360535-0FEF7503-5650-47CD-A68A-65F9978FE799Q37368521-C02318F0-694B-4351-BAA2-B7F3E63F838AQ37554162-A29D248B-CF13-47D4-8F30-5C39CB278CF8Q37564537-F2C63E8A-E6BF-4946-B26F-7C653859E376Q37593083-9725BBA9-1F04-42DA-B06D-B9EAA88202F8Q37625241-1197C338-A150-40B4-9FCB-956E09621735Q37686640-526F9CA1-3188-426A-804A-5DF0A21FB6A2Q37810816-F54DFA17-64B6-4728-B3F3-5ED07753B248Q38003426-48F0FF6A-AFDB-44BB-90FF-B9840A9391B8Q38066148-BF3D1F52-76F1-4CDC-91D4-8ED8F88CFB21Q38068954-84B8B89A-1768-4354-A4BA-A0956452ACC7Q38162959-A3A792FC-5465-4DD1-B4B1-69CBA4F6384BQ38172276-B868EC4E-DAF3-41BD-BEEF-1214AD7C2D90Q38362427-C8E80CC6-84E0-45FD-BD08-B04D31785DB6Q38461061-ACA4B496-B481-4A65-B7F9-2AC93ADE3651Q38727453-4A7229EF-2549-47DD-8E74-A6573C9045AAQ38848809-F17B9C03-A9CC-418E-820F-E9678D87CC51Q39169219-390310B0-8262-419B-A3C4-A1ECB50D97BD
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Chitosan for mucosal vaccination.
@ast
Chitosan for mucosal vaccination.
@en
Chitosan for mucosal vaccination.
@nl
type
label
Chitosan for mucosal vaccination.
@ast
Chitosan for mucosal vaccination.
@en
Chitosan for mucosal vaccination.
@nl
prefLabel
Chitosan for mucosal vaccination.
@ast
Chitosan for mucosal vaccination.
@en
Chitosan for mucosal vaccination.
@nl
P2093
P1476
Chitosan for mucosal vaccination.
@en
P2093
Borchard G
Junginger HE
Verhoef JC
van der Lubben IM
P304
P356
10.1016/S0169-409X(01)00197-1
P407
P577
2001-11-01T00:00:00Z